Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2006

Axela Biosensors and Abnova to Co-Develop Biomarker Panels

  • Axela Biosensors and Abnova signed a collaborative agreement to co-develop reagents and biomarker panels for use on Axela’s dotLab System. The dotLab System provides for the analysis, validation, and commercialization of protein biomarkers.

    “These products will target a significant bottleneck in biomarker validation,” says Wilber Huang, president of Abnova. “Our ability to generate highly specific antibodies on an industrial scale combined with the levels of sensitivity and quantitation of the dotLab System will improve and accelerate the ability of pharmaceutical and translational medicine researchers to validate medically important biomarkers.”

    Abnova will optimize a series of Mabs for the quantitation of specific serum protein biomarkers for use with Axela’s dotLab Sensors. Researchers will be able to combine these Mabs with their own reagents to create custom panels for multiplexed biomarker detection.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »